Robin Swartz Sells 6,500 Shares of Voyager Therapeutics, Inc. (NASDAQ:VYGR) Stock

Voyager Therapeutics, Inc. (NASDAQ:VYGR) COO Robin Swartz sold 6,500 shares of the company’s stock in a transaction on Monday, December 23rd. The stock was sold at an average price of $5.65, for a total transaction of $36,725.00. Following the transaction, the chief operating officer now owns 112,328 shares of the company’s stock, valued at approximately $634,653.20. The trade was a 5.47 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link.

Voyager Therapeutics Trading Up 2.2 %

Shares of NASDAQ VYGR traded up $0.13 during midday trading on Thursday, reaching $5.91. 325,253 shares of the stock were exchanged, compared to its average volume of 624,445. The company has a market capitalization of $322.84 million, a P/E ratio of 8.32 and a beta of 0.90. The stock has a 50 day moving average price of $6.39 and a 200-day moving average price of $7.02. Voyager Therapeutics, Inc. has a 52-week low of $5.19 and a 52-week high of $11.72.

Voyager Therapeutics (NASDAQ:VYGR) last issued its quarterly earnings results on Tuesday, November 12th. The company reported ($0.16) earnings per share for the quarter, beating the consensus estimate of ($0.45) by $0.29. Voyager Therapeutics had a return on equity of 8.33% and a net margin of 15.80%. The company had revenue of $24.63 million during the quarter, compared to the consensus estimate of $12.63 million. During the same period in the previous year, the firm posted ($0.59) EPS. On average, analysts forecast that Voyager Therapeutics, Inc. will post -0.89 earnings per share for the current year.

Hedge Funds Weigh In On Voyager Therapeutics

Large investors have recently added to or reduced their stakes in the business. Armistice Capital LLC grew its holdings in Voyager Therapeutics by 11.3% in the second quarter. Armistice Capital LLC now owns 5,200,000 shares of the company’s stock valued at $41,132,000 after purchasing an additional 528,000 shares during the period. Great Point Partners LLC acquired a new position in shares of Voyager Therapeutics in the 2nd quarter valued at $12,668,000. Geode Capital Management LLC grew its stake in shares of Voyager Therapeutics by 0.6% during the 3rd quarter. Geode Capital Management LLC now owns 1,079,509 shares of the company’s stock valued at $6,316,000 after buying an additional 6,740 shares during the period. Erste Asset Management GmbH acquired a new stake in shares of Voyager Therapeutics during the 3rd quarter worth $6,192,000. Finally, American Century Companies Inc. raised its position in shares of Voyager Therapeutics by 32.4% in the 2nd quarter. American Century Companies Inc. now owns 1,019,332 shares of the company’s stock worth $8,063,000 after buying an additional 249,659 shares during the period. 48.03% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of equities research analysts recently commented on the stock. StockNews.com downgraded shares of Voyager Therapeutics from a “buy” rating to a “hold” rating in a research report on Friday, December 13th. Leerink Partnrs upgraded Voyager Therapeutics to a “strong-buy” rating in a research report on Wednesday, October 16th. Canaccord Genuity Group reaffirmed a “buy” rating and set a $14.00 price target on shares of Voyager Therapeutics in a research note on Thursday, November 14th. HC Wainwright restated a “buy” rating and set a $30.00 target price on shares of Voyager Therapeutics in a report on Thursday, November 14th. Finally, Citigroup initiated coverage on shares of Voyager Therapeutics in a report on Monday, December 2nd. They issued a “buy” rating and a $12.00 price target on the stock. One investment analyst has rated the stock with a hold rating, eight have given a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, Voyager Therapeutics presently has a consensus rating of “Buy” and an average target price of $17.00.

Voyager Therapeutics Company Profile

Voyager Therapeutics, Inc, a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial.